Thank you very much, Mr. Chair. I'll just pull up my opening remarks. I'll be very brief here.
Thank you very much for the opportunity to appear before you today. It is my pleasure to appear before this committee as it studies issues of conflicts of interest and the Lobbying Act in relation to pandemic spending.
Just as all departments have been called on to protect Canadians and our economy during this extraordinary time, Innovation, Science and Economic Development Canada, ISED, has been hard at work, doing its part to help deliver a strong, immediate and effective response.
The integrity and commitment displayed within ISED as we develop and implement pandemic programming has been exemplary.
For example, the government's call to action to Canadian industry attracted more than 6,600 companies, all offering their expertise and capacity to help combat COVID-19. I believe the ministry that I'm in charge of moved swiftly to work with these companies. In fact, in a very short period we went from sourcing barely any of our personal protective equipment domestically, for example, to sourcing approximately 40% of the total value of COVID-19-related PPE contracts in Canada.
This is a significant pivot by Canadian industry, and we were very proud to help facilitate that by shifting the focus, for example, of our business innovation programming to concentrate directly on COVID-19. I'm talking here about programs such as the strategic innovation fund, the innovation superclusters, Innovative Solutions Canada and the National Research Council's industrial research assistance program. With all hands on deck, we aimed to expedite the evaluation and approval of projects so that they could get off the ground quickly to address the most urgent issues.
Without a doubt, the groundwork that we laid in previously establishing collaborative innovation programs really set us up to respond quickly and successfully. Of course, the best way to end this pandemic is with a safe and effective vaccine and related medical countermeasures, and so, Mr. Chair, we solicited the participation of industry and identified medical experts to lead independent task forces for vaccines and therapeutics respectively. In doing so, we gained insight into very technical subject matter and received invaluable advice as the government moved to fund related projects in a timely manner.
I'd like to commend my own staff for their action in securing access to needed supplies and working with colleagues in other ministries to secure access to vaccine candidates for Canadians.
Mr. Chair, in all of these instances, Innovation, Science and Economic Development Canada and its officials acted with transparency, extending assistance and offering solutions to the greatest challenge any of us have faced in our lifetime.
I can say with confidence that it has been—